Literature DB >> 10395699

Alloantibody-mediated class I signal transduction in endothelial cells and smooth muscle cells: enhancement by IFN-gamma and TNF-alpha.

H Bian1, E F Reed.   

Abstract

Chronic rejection is the major limiting factor to long term survival of solid organ allografts. The hallmark of chronic rejection is transplant atherosclerosis, which is characterized by the intimal proliferation of smooth muscle cells, endothelial cells, and fibroblasts, leading to vessel obstruction, fibrosis, and eventual graft loss. The mechanism of chronic rejection is poorly understood, but it is suspected that the associated vascular changes are a result of anti-HLA Ab-mediated injury to the endothelium and smooth muscle of the graft. In this study we have investigated whether anti-HLA Abs, developed by transplant recipients following transplantation, are capable of transducing signals via HLA class I molecules, which stimulate cell proliferation. In this report we show that ligation of class I molecules with Abs to distinct HLA-A locus and HLA-B locus molecules results in increased tyrosine phosphorylation of intracellular proteins and induction of fibroblast growth factor receptor expression on endothelial and smooth muscle cells. Treatment of cells with IFN-gamma and TNF-alpha up-regulated MHC class I expression and potentiated anti-HLA Ab-induced fibroblast growth factor receptor expression. Engagement of class I molecules also stimulated enhanced proliferative responses to basic fibroblast growth factor, which augmented endothelial cell proliferation. These findings support a role for anti-HLA Abs and cytokines in the transduction of proliferative signals, which stimulate the development of myointimal hyperplasia associated with chronic rejection of human allografts.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10395699

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Determination of the frequency of HLA antibody secreting B-lymphocytes in alloantigen sensitized individuals.

Authors:  A Mulder; M J Kardol; J Kamp; C Uit Het Broek; G M Schreuder; I I Doxiadis; F H Claas
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

2.  A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody.

Authors:  T Hirohashi; C M Chase; P Della Pelle; D Sebastian; A Alessandrini; J C Madsen; P S Russell; R B Colvin
Journal:  Am J Transplant       Date:  2011-11-09       Impact factor: 8.086

3.  Lymphoid neogenesis in chronic rejection: evidence for a local humoral alloimmune response.

Authors:  Olivier Thaunat; Anne-Christine Field; Jianping Dai; Liliane Louedec; Natacha Patey; Marie-Françoise Bloch; Chantal Mandet; Marie-France Belair; Patrick Bruneval; Olivier Meilhac; Blanche Bellon; Etienne Joly; Jean-Baptiste Michel; Antonino Nicoletti
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-28       Impact factor: 11.205

4.  Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation.

Authors:  Gary S Hill; Dominique Nochy; Patrick Bruneval; J P Duong van Huyen; Denis Glotz; Caroline Suberbielle; Julien Zuber; Dany Anglicheau; Jean-Philippe Empana; Christophe Legendre; Alexandre Loupy
Journal:  J Am Soc Nephrol       Date:  2011-04-14       Impact factor: 10.121

Review 5.  Effector mechanisms of rejection.

Authors:  Aurélie Moreau; Emilie Varey; Ignacio Anegon; Maria-Cristina Cuturi
Journal:  Cold Spring Harb Perspect Med       Date:  2013-11-01       Impact factor: 6.915

Review 6.  The link between major histocompatibility complex antibodies and cell proliferation.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  Transplant Rev (Orlando)       Date:  2011-07-30       Impact factor: 3.943

7.  Nanoparticle targeting to the endothelium during normothermic machine perfusion of human kidneys.

Authors:  Gregory T Tietjen; Sarah A Hosgood; Jenna DiRito; Jiajia Cui; Deeksha Deep; Eric Song; Jan R Kraehling; Alexandra S Piotrowski-Daspit; Nancy C Kirkiles-Smith; Rafia Al-Lamki; Sathia Thiru; J Andrew Bradley; Kourosh Saeb-Parsy; John R Bradley; Michael L Nicholson; W Mark Saltzman; Jordan S Pober
Journal:  Sci Transl Med       Date:  2017-11-29       Impact factor: 17.956

8.  Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus.

Authors:  Y-P Jin; N M Valenzuela; M E Ziegler; E Rozengurt; E F Reed
Journal:  Am J Transplant       Date:  2014-03-01       Impact factor: 8.086

9.  Report from a consensus conference on the sensitized patient awaiting heart transplantation.

Authors:  Jon Kobashigawa; Mandeep Mehra; Lori West; Ronald Kerman; James George; Marlene Rose; Adriana Zeevi; Nancy Reinsmoen; Jignesh Patel; Elaine F Reed
Journal:  J Heart Lung Transplant       Date:  2009-03       Impact factor: 10.247

10.  Effect of maternal anti-HPA-1a antibodies and polyclonal IVIG on the activation status of vascular endothelial cells.

Authors:  C M Radder; H Beekhuizen; H H H Kanhai; A Brand
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.